| Literature DB >> 26037731 |
Scott E Kasner1, Le Wang, Benjamin French, Steven R Messe, Richard Horenstein, Emile R Mohler, James A S Muldowney, Jonas Ellenberg, Stephen E Kimmel.
Abstract
BACKGROUND AND OBJECTIVES: Dosing algorithms for warfarin incorporate clinical and genetic factors but may not account for the numerous comorbidities affecting patients who start warfarin while hospitalized. We aimed to determine whether these algorithms perform differently when warfarin is initiated for inpatients compared with outpatients. PATIENTS AND METHODS: We analyzed a prospective cohort of 1015 participants from the Clarification of Optimal Anticoagulation through Genetics (COAG) trial who were randomized to either pharmacogenetically or clinically guided warfarin dosing algorithms. Clinicians and participants were blinded to dose during the first 28 days. We compared groups, based on location at the time of the first warfarin dose request, in relation to the following outcomes: percentage of time in the therapeutic international normalized ratio (INR) range (PTTR) during the first 4 weeks, time to first therapeutic INR, time to maintenance dose, and the difference between predicted and observed maintenance doses.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26037731 PMCID: PMC4508217 DOI: 10.1007/s40256-015-0126-3
Source DB: PubMed Journal: Am J Cardiovasc Drugs ISSN: 1175-3277 Impact factor: 3.571